JP2021510376A5 - - Google Patents

Info

Publication number
JP2021510376A5
JP2021510376A5 JP2020538691A JP2020538691A JP2021510376A5 JP 2021510376 A5 JP2021510376 A5 JP 2021510376A5 JP 2020538691 A JP2020538691 A JP 2020538691A JP 2020538691 A JP2020538691 A JP 2020538691A JP 2021510376 A5 JP2021510376 A5 JP 2021510376A5
Authority
JP
Japan
Prior art keywords
unsubstituted
cancer
substituted
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
JP2020538691A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019139899A5 (https=
JP2021510376A (ja
JP7355741B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/012695 external-priority patent/WO2019139899A1/en
Publication of JP2021510376A publication Critical patent/JP2021510376A/ja
Publication of JPWO2019139899A5 publication Critical patent/JPWO2019139899A5/ja
Publication of JP2021510376A5 publication Critical patent/JP2021510376A5/ja
Priority to JP2023156385A priority Critical patent/JP2024001052A/ja
Application granted granted Critical
Publication of JP7355741B2 publication Critical patent/JP7355741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020538691A 2018-01-10 2019-01-08 ベンズアミド化合物 Active JP7355741B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023156385A JP2024001052A (ja) 2018-01-10 2023-09-21 ベンズアミド化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862615857P 2018-01-10 2018-01-10
US62/615,857 2018-01-10
PCT/US2019/012695 WO2019139899A1 (en) 2018-01-10 2019-01-08 Benzamide compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023156385A Division JP2024001052A (ja) 2018-01-10 2023-09-21 ベンズアミド化合物

Publications (4)

Publication Number Publication Date
JP2021510376A JP2021510376A (ja) 2021-04-22
JPWO2019139899A5 JPWO2019139899A5 (https=) 2022-01-17
JP2021510376A5 true JP2021510376A5 (https=) 2022-01-17
JP7355741B2 JP7355741B2 (ja) 2023-10-03

Family

ID=67218673

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020538692A Pending JP2021510165A (ja) 2018-01-10 2019-01-08 ベンズアミド化合物
JP2020538644A Pending JP2021510163A (ja) 2018-01-10 2019-01-08 ベンズアミド化合物
JP2020538691A Active JP7355741B2 (ja) 2018-01-10 2019-01-08 ベンズアミド化合物
JP2023156385A Pending JP2024001052A (ja) 2018-01-10 2023-09-21 ベンズアミド化合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020538692A Pending JP2021510165A (ja) 2018-01-10 2019-01-08 ベンズアミド化合物
JP2020538644A Pending JP2021510163A (ja) 2018-01-10 2019-01-08 ベンズアミド化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023156385A Pending JP2024001052A (ja) 2018-01-10 2023-09-21 ベンズアミド化合物

Country Status (16)

Country Link
US (7) USRE50643E1 (https=)
EP (4) EP3737681A4 (https=)
JP (4) JP2021510165A (https=)
KR (4) KR20200108301A (https=)
CN (5) CN111801320A (https=)
AR (4) AR114998A1 (https=)
AU (4) AU2019207608B2 (https=)
BR (3) BR112020014151A2 (https=)
CA (3) CA3087262A1 (https=)
ES (1) ES3013457T3 (https=)
IL (4) IL316472A (https=)
MX (4) MX2020007392A (https=)
RU (2) RU2020120928A (https=)
SG (3) SG11202005784YA (https=)
TW (5) TW201934550A (https=)
WO (4) WO2019139899A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
HUE060310T2 (hu) 2017-04-18 2023-02-28 Shanghai Fochon Pharmaceutical Co Ltd Apoptosis-indukáló szerek
EP3737681A4 (en) 2018-01-10 2022-01-12 Recurium IP Holdings, LLC BENZAMIDE COMPOUNDS
WO2021007307A1 (en) * 2019-07-10 2021-01-14 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
US20220273666A1 (en) * 2019-07-10 2022-09-01 Recurium Ip Holdings, Llc Nanoparticle formulation of bcl-2 inhibitor
KR20220100992A (ko) 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여
AU2020407070A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
JP2023508324A (ja) * 2019-12-20 2023-03-02 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 組み合わせ
MX2022007623A (es) * 2019-12-20 2022-09-23 Recurium Ip Holdings Llc Combinaciones.
AU2020404995A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
KR20220143909A (ko) 2020-02-21 2022-10-25 리커리엄 아이피 홀딩스, 엘엘씨 디플루오로메틸 요오도 화합물 및 방법
MX2022010512A (es) * 2020-04-28 2022-11-16 Recurium Ip Holdings Llc Inhibidores de proteína bcl-2.
CN115666574A (zh) * 2020-05-07 2023-01-31 里科瑞尔姆Ip控股有限责任公司 组合
CN116133661A (zh) * 2020-05-19 2023-05-16 里科瑞尔姆Ip控股有限责任公司 淀粉样变性的治疗
US20230250077A1 (en) * 2020-07-10 2023-08-10 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Sulfonylbenzamide derivative and conjugate thereof, preparation method therefor and use thereof
JP2023545498A (ja) * 2020-10-16 2023-10-30 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Ｂｃｌ－２阻害剤と化学療法剤との組み合わせ
WO2022133446A1 (en) * 2020-12-16 2022-06-23 Recurium Ip Holdings, Llc Combinations
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途
CN113816889B (zh) * 2021-10-11 2023-08-22 中国药科大学 一类4-磺酰亚胺-1H-吡咯类Mcl-1抑制剂及其抗肿瘤医药用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
JP2003096461A (ja) 2001-09-25 2003-04-03 Fuji Photo Film Co Ltd 液晶組成物およびそれを用いた液晶素子
DE10217814A1 (de) 2002-04-22 2003-11-13 Ibfb Pharma Gmbh Neue tricyclische Mercaptane, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
JP4628140B2 (ja) 2005-03-03 2011-02-09 富士フイルム株式会社 セルロースアシレートフィルム、偏光板および液晶表示装置
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
US20100234364A1 (en) 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
CA2662320C (en) 2006-09-05 2014-07-22 Abbott Laboratories Bcl inhibitors treating platelet excess
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
EP2094672B1 (en) 2006-11-15 2013-05-29 Genentech, Inc. Arylsulfonamide compounds
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
RU2009125575A (ru) * 2006-12-04 2011-01-20 Эбботт Лэборетриз (Us) Комплексные диагностические анализы для терапии рака
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
HUE029289T2 (en) 2008-12-05 2017-02-28 Abbvie Inc Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CN102282128B (zh) 2009-01-19 2015-06-17 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ595708A (en) 2009-05-26 2014-03-28 Abbvie Bahamas Ltd Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
MX2011013797A (es) 2009-06-18 2012-01-30 Abbott Lab Suspension de farmaco estable de nanoparticula.
WO2010148422A1 (en) 2009-06-25 2010-12-29 Walter And Eliza Hall Institute Of Medical Research Compounds and methods for treating parasitic infestations
IN2012DN01325A (https=) 2009-08-20 2015-06-05 Karus Therapeutics Ltd
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
PH12013500954A1 (en) 2010-11-11 2017-05-19 Redx Pharma Plc Drug derivatives
TWI620736B (zh) 2010-11-23 2018-04-11 艾伯維巴哈馬有限公司 使用選擇性ｂｃｌ-２抑制劑之治療方法
SG192126A1 (en) 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2013185202A1 (en) 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
KR102318204B1 (ko) 2013-01-16 2021-10-26 더 리젠츠 오브 더 유니버시티 오브 미시간 Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법
UY39848A (es) 2013-03-13 2022-09-30 Abbvie Ireland Unlimited Co Procesos para la preparación de un agente inductor de la apoptosis
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2907960C (en) 2013-05-22 2021-10-19 Children's Hospital Medical Center Combination therapy for mds
US10364250B2 (en) 2013-05-24 2019-07-30 Mark Barry HAMPTON Bioactive compounds
JP6730183B2 (ja) 2013-07-12 2020-07-29 ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー シストバクトアミド（Ｃｙｓｔｏｂａｃｔａｍｉｄｅｓ）
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
CN105012318B (zh) 2014-04-17 2020-02-11 沈华浩 磺酰胺类化合物在气道慢性炎症性疾病中的应用
CN104131034B (zh) 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
WO2016025652A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a bcl-2 pathway modulator and related methods
CN106999451B (zh) * 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
CA2981753A1 (en) 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditions
WO2016131100A1 (en) 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
EP3285775B1 (en) * 2015-04-20 2020-04-15 Mayo Foundation for Medical Education and Research Methods and materials for killing hiv infected cells
PT3302549T (pt) 2015-05-26 2019-09-09 H Hoffnabb La Roche Ag Terapêutica combinada de um anticorpo anti-cd20 com um inibidor de bcl-2 e um inibidor de mdm2
GB201513481D0 (en) 2015-07-30 2015-09-16 Univ Manchester Inhibitor compounds
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN106608895A (zh) 2015-10-21 2017-05-03 苏州国匡医药科技有限公司 一类具有糖环结构的bcl-2选择性抑制剂及其用途
US11111259B2 (en) 2015-12-18 2021-09-07 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
CN106957315B (zh) 2016-01-08 2019-08-13 中国人民解放军第二军医大学 N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
WO2017123616A1 (en) 2016-01-11 2017-07-20 Merrimack Pharmaceuticals, Inc. Inhibiting b-cell lymphoma 2 (bcl-2) and related proteins
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
JP6936498B2 (ja) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
CA3026651A1 (en) 2016-06-09 2017-12-14 Blinkbio, Inc. Silanol based therapeutic payloads
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN106565607B (zh) 2016-10-11 2019-03-26 湖北泓肽生物科技有限公司 一种l-肌肽的合成方法
CN106565706B (zh) 2016-10-27 2018-05-01 广东东阳光药业有限公司 一种磺酰胺衍生物及其在药学中的应用
CN106749233B (zh) 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
WO2018146506A1 (en) 2017-02-10 2018-08-16 Universitat Politècnica De València Therapeutic derivatives
CN107089981A (zh) 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
EP3737681A4 (en) 2018-01-10 2022-01-12 Recurium IP Holdings, LLC BENZAMIDE COMPOUNDS
SI3788042T1 (sl) 2018-04-29 2025-06-30 Beigene Switzerland Gmbh Zaviralci BCL-2
US12097194B2 (en) 2018-09-18 2024-09-24 Signalchem Lifesciences Corporation Combination therapy for treating blood cancer

Similar Documents

Publication Publication Date Title
JP2021510376A5 (https=)
TWI837478B (zh) 用於治療ｂｒａｆ相關的疾病和病症之化合物
IL275762B1 (en) Derivatives of phenyl-so2-nh-c(=o)-phenyl-piperazine-ch2-1,2-cyclohexane-bicyclo[1.1.1]pentane and pharmaceutical compositions comprising them
CN101678029B (zh) 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途
KR20210087440A (ko) 삼중 음성 유방암의 치료를 위한 병용 요법
TW202136252A (zh) 化合物及其用途
JP7307744B2 (ja) がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体
WO2020027083A1 (ja) キナゾリン化合物を有効成分とする医薬組成物
JPWO2019139899A5 (https=)
JP5852678B2 (ja) 抗腫瘍剤の効果増強剤
UA119150C2 (uk) СПОСОБИ ЛІКУВАННЯ З ВИКОРИСТАННЯМ СЕЛЕКТИВНИХ ІНГІБІТОРІВ Всl-2
JP2016523974A5 (https=)
CN111643504A (zh) Akt抑制剂化合物和化疗剂的组合以及使用方法
JP2021501756A5 (https=)
JP2015520143A5 (https=)
EP2694073B1 (en) Combinations of akt and mek inhibitors for treating cancer
JP7214632B2 (ja) ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
KR20190110581A (ko) 암 치료
JP2019511554A (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
EP3603638A1 (en) COMBINATION THERAPY TECHNIQUE FOR Axl INHIBITORY AGENT AND EGFR TYROSINE KINASE INHIBITOR
US20260041669A1 (en) Solid forms of a cdk inhibitor
CA3157778A1 (en) Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
CN114173779A (zh) 对抗ccr4抗体具有抗性的癌症的治疗剂
JP2020536844A (ja) キノリンおよびナフチリジンの誘導体および組成物
JPWO2021127044A5 (https=)